NASDAQ:ZLAB - Zai Lab Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $16.43 -0.48 (-2.84 %) (As of 11/13/2018 02:01 AM ET)Previous Close$16.91Today's Range$16.23 - $16.9552-Week Range$14.29 - $28.43Volume26,887 shsAverage Volume95,583 shsMarket Capitalization$982.56 millionP/E Ratio-7.08Dividend YieldN/ABeta2.7 ProfileDiscussionAnalyst RatingsChartFinancialsInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Zai Lab Limited, a biopharmaceutical company, engages in discovering or licensing, developing, and commercializing proprietary therapeutics that address medical needs in the fields of oncology, and autoimmune and infectious disease therapies in the People's Republic of China. Its drug candidates include ZL-2306, a poly ADP ribose polymerase 1/2 inhibitor, which is in Phase III clinical trial for the treatment of ovarian, lung, and breast cancers; ZL-2401, an antibiotic that is in Phase III clinical trial to treat ABSSSI, CABP, and UTI; FPA144, a humanized monoclonal antibody, which is in Phase I/III clinical trial to treat gastric and gastroesophageal cancer; ETX2514, a novel ß-lactamase inhibitor that is in Phase II cUTI trial for the treatment of acinetobacter baumannii; and ZL-2301, which is in Phase III clinical trial to treat HCC. The company's drug candidates also comprise ZL-3101, a novel steroid-sparing topical product that is in Phase II clinical trial for the treatment of eczema and psoriasis; and ZL-2302 to treat non-small cell lung cancer. The company, through its subsidiary, Zai Lab (Shanghai) Co. Ltd., has a collaboration agreement with the NovoCure Limited to perform clinical studies, sell, and import tumor treating field products in the field of oncology. Zai Lab Limited was founded in 2013 and is headquartered in Shanghai, the People's Republic of China. Receive ZLAB News and Ratings via Email Sign-up to receive the latest news and ratings for ZLAB and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ZLAB Previous Symbol CUSIPN/A Webwww.zailaboratory.com Phone86-21-6163-2588 Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Price-To-Earnings Trailing P/E Ratio-7.08 Forward P/E Ratio-9.23 P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / CashN/A Book Value$4.77 per share Price / Book3.44 Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/A Miscellaneous Employees88 Outstanding Shares58,100,000Market Cap$982.56 million OptionableOptionable Zai Lab (NASDAQ:ZLAB) Frequently Asked Questions What is Zai Lab's stock symbol? Zai Lab trades on the NASDAQ under the ticker symbol "ZLAB." What price target have analysts set for ZLAB? 2 analysts have issued twelve-month price targets for Zai Lab's stock. Their predictions range from $32.00 to $43.00. On average, they anticipate Zai Lab's stock price to reach $37.50 in the next year. This suggests a possible upside of 128.2% from the stock's current price. View Analyst Price Targets for Zai Lab. What is the consensus analysts' recommendation for Zai Lab? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Zai Lab in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Zai Lab. Has Zai Lab been receiving favorable news coverage? News stories about ZLAB stock have been trending negative this week, InfoTrie reports. The research firm identifies positive and negative news coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Zai Lab earned a news impact score of -2.7 on InfoTrie's scale. They also gave news articles about the company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an impact on the company's share price in the near future. Are investors shorting Zai Lab? Zai Lab saw a decline in short interest in the month of October. As of October 15th, there was short interest totalling 419,534 shares, a decline of 65.0% from the September 28th total of 1,199,568 shares. Based on an average daily trading volume, of 231,181 shares, the days-to-cover ratio is currently 1.8 days. Approximately 0.7% of the company's shares are short sold. View Zai Lab's Current Options Chain. Who are some of Zai Lab's key competitors? Some companies that are related to Zai Lab include Horizon Pharma (HZNP), Array Biopharma (ARRY), FibroGen (FGEN), Emergent Biosolutions (EBS), Ligand Pharmaceuticals (LGND), Intercept Pharmaceuticals (ICPT), Evotec (EVTCY), Endo International (ENDP), Madrigal Pharmaceuticals (MDGL), Ascendis Pharma A/S (ASND), Blueprint Medicines (BPMC), Ultragenyx Pharmaceutical (RARE), Mallinckrodt (MNK), Supernus Pharmaceuticals (SUPN) and ACADIA Pharmaceuticals (ACAD). Who are Zai Lab's key executives? Zai Lab's management team includes the folowing people: Dr. Ying Du, Chairman & CEO (Age 52)Mr. Tao Fu, Pres, COO & Director (Age 46)Mr. Ki Chul Cho, Chief Financial Officer (Age 41)Dr. Ning Xu, Exec. VP of Clinical Operations & Regulatory Affairs (Age 53)Dr. Qi Liu, Chief Medical Officer of Oncology (Age 53) When did Zai Lab IPO? (ZLAB) raised $100 million in an initial public offering on Wednesday, September 20th 2017. The company issued 5,900,000 shares at a price of $16.00-$18.00 per share. J.P. Morgan, Citigroup and Leerink Partners served as the underwriters for the IPO. Who are Zai Lab's major shareholders? Zai Lab's stock is owned by many different of institutional and retail investors. Top institutional shareholders include FMR LLC (10.00%), Segantii Capital Management Ltd (4.13%), Gilder Gagnon Howe & Co. LLC (1.44%), Sumitomo Mitsui Trust Holdings Inc. (0.36%), BlackRock Inc. (0.18%) and Cambiar Investors LLC (0.04%). Which institutional investors are selling Zai Lab stock? ZLAB stock was sold by a variety of institutional investors in the last quarter, including Gilder Gagnon Howe & Co. LLC. Which institutional investors are buying Zai Lab stock? ZLAB stock was purchased by a variety of institutional investors in the last quarter, including Segantii Capital Management Ltd, FMR LLC, BlackRock Inc., Cambiar Investors LLC, Bank of Montreal Can and Sumitomo Mitsui Trust Holdings Inc.. How do I buy shares of Zai Lab? Shares of ZLAB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Zai Lab's stock price today? One share of ZLAB stock can currently be purchased for approximately $16.43. How big of a company is Zai Lab? Zai Lab has a market capitalization of $982.56 million. The company earns $-50,380,000.00 in net income (profit) each year or ($2.32) on an earnings per share basis. Zai Lab employs 88 workers across the globe. What is Zai Lab's official website? The official website for Zai Lab is http://www.zailaboratory.com. How can I contact Zai Lab? Zai Lab's mailing address is 4560 JINKE ROAD BLDG. 1 FOURTH FLOOR PUDONG, SHANGHAI F4, 201210. The company can be reached via phone at 86-21-6163-2588 or via email at [email protected] MarketBeat Community Rating for Zai Lab (NASDAQ ZLAB)Community Ranking: 2.2 out of 5 ( )Outperform Votes: 104 (Vote Outperform)Underperform Votes: 136 (Vote Underperform)Total Votes: 240MarketBeat's community ratings are surveys of what our community members think about Zai Lab and other stocks. Vote "Outperform" if you believe ZLAB will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ZLAB will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 11/13/2018 by MarketBeat.com StaffFeatured Article: What are the benefits of a balanced fund?